April has been the busiest regulatory month since the war began. Eleven FDA decisions. A ceasefire extended indefinitely. A Lebanon ceasefire extended three more weeks. And now — the final three days.
What Just Resolved
FDA cited CMC deficiencies — packaging leachables, toxicology risk assessments, manufacturing issues at the contract manufacturing organization. No additional clinical data requested. Grace plans a Type A meeting and resubmission. The 40-year wait continues.
Merck's doravirine/islatravir approved as IDVYNSO — first non-INSTI, tenofovir-free, once-daily two-drug HIV regimen. Non-inferior to Biktarvy in Phase 3. PDUFA was April 28. Available in pharmacies after May 11.
April 28–30: Five Binaries
The last three days of April deliver the densest regulatory cluster since the triple binary of April 10. Every event below produces a definitive outcome. Here is what the calendar says.
| Date | Agency | Event | Tickers |
|---|---|---|---|
| Apr 28 | USTR/ITC | Section 301 hearings begin (forced labor track) | Supply chains |
| Apr 28–29 | FOMC | Rate decision (2 PM ET Apr 29) + Powell presser | Broad |
| ~Apr 29 | Congress | War Powers Act Day 60 | Defense, energy |
| Apr 30 AM | FDA/ODAC | Camizestrant AdCom (HR+ breast cancer) | AZN |
| Apr 30 PM | FDA/ODAC | Truqap/capivasertib AdCom (mHSPC) | AZN |
| Apr 30 | FDA | AXS-05 sNDA PDUFA (Alzheimer's agitation) | AXSM |
What Each One Means
FOMC: The Statement Is the Event
Markets price a 99.4% probability of a hold at 3.50–3.75%. The decision itself is not the binary — the language is. This is not a projections meeting. No dot plot. No updated Summary of Economic Projections. Every word in the statement carries outsized weight.
The question Powell must answer: is the inflation overshoot (CPI 3.3% YoY, driven by energy) temporary or structural? JPMorgan expects a hold through all of 2026, with a possible hike in Q3 2027. If the statement signals any pivot toward acknowledging structural inflation, the curve reprices immediately.
War Powers: Day 60
Under the War Powers Resolution, the president must terminate military operations after 60 days unless Congress authorizes force. Hostilities began February 28. Formal congressional notification was March 2 — making the technical deadline May 1, with April 29 as the practical marker.
Congress has not authorized force. The Senate has blocked war powers resolutions four times along party lines. The House voted one down 213–214. No public hearings. No oversight. Trump will almost certainly invoke the 30-day extension provision, citing troop safety. The binary is not whether operations continue — they will — but whether any institutional check emerges. So far, none has.
ODAC: The Return of Advisory Committees
The Oncologic Drugs Advisory Committee has not met in nine months. April 30 breaks the drought with a double session — both AstraZeneca drugs.
Oral SERD + CDK4/6 inhibitor for ESR1-mutant HR+/HER2− metastatic breast cancer. SERENA-6 Phase 3: 56% improvement in progression-free survival. If the panel votes favorably, camizestrant becomes AstraZeneca's anchor in the next generation of endocrine therapy.
Expansion into PTEN-deficient metastatic hormone-sensitive prostate cancer, combined with abiraterone. CAPItello-281 Phase 3 showed significant radiographic PFS improvement. A favorable vote extends Truqap's reach from breast cancer into prostate.
This is the first ODAC under the post-Pazdur FDA. The panel's tone — how questions are asked, what standards are applied — will signal the regulatory temperature for every oncology filing that follows.
AXS-05: First Treatment for Alzheimer's Agitation
Axsome Therapeutics' supplemental NDA for AXS-05 (dextromethorphan/bupropion, already approved as AUVELITY for depression) carries a Priority Review designation. The PDUFA target is April 30.
Up to 76% of Alzheimer's patients experience agitation. There is currently no FDA-approved treatment. ACCORD-1 Phase 3 met its primary endpoint — significant delay in time to relapse of agitation. If approved, AXS-05 becomes the first drug specifically indicated for this population.
Calendar Forward
| Date | Event |
|---|---|
| May 5 | AMD earnings + Section 301 hearings (semiconductors) |
| May 9 | ATA188 BLA PDUFA (progressive MS) |
| May 13 | VST earnings |
| May 15 | 13F filing deadline (Q1 2026) + Avutometinib NDA PDUFA |
| ~May 17 | Lebanon ceasefire expiry (extended Apr 23) |
| May 24 | Leqembi SC sBLA PDUFA (Alzheimer's) |
| Jun 2 | AWS-3 spectrum auction opens |
April delivered eleven FDA decisions, two early approvals, three CRLs, a ceasefire extended twice, and a blockade that has turned 28 ships. Three days remain.